Ptc Therapeutics (PTCT) Cash from Financing Activities (2012 - 2026)

Ptc Therapeutics' Cash from Financing Activities history runs 15 years deep, the most recent figure standing at $211.9 million for Q2 2026.

• In Q2 2026, Cash from Financing Activities rose 5249.1% year-over-year to $211.9 million; the TTM figure through Jun 2026 stood at $536.0 million (up 2312.8% YoY), while the FY2025 annual figure was $331.1 million, up 29.4% from the prior year.
• Cash from Financing Activities for Q2 2026 stood at $211.9 million, up from $6.4 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $620.5 million in Q4 2023, with the low at -$140.0 million in Q3 2022.
• The 5-year median for Cash from Financing Activities is $7.9 million (2025), against an average of $90.0 million.
• Peak annual rise in Cash from Financing Activities reached 6857.23% in 2022, while the deepest fall reached 4804.13% in 2022.
• Ptc Therapeutics' Cash from Financing Activities stood at $302.9 million in 2022, then surged by 104.84% to $620.5 million in 2023, then sank by 95.73% to $26.5 million in 2024, then soared by 1042.78% to $302.5 million in 2025, then declined by 29.96% to $211.9 million in 2026.
• Business Quant data shows PTCT's Cash from Financing Activities at $211.9 million in Q2 2026, $6.4 million in Q1 2026, and $302.5 million in Q4 2025.